National and Kapodistrian University of Athens
COVID-19 infection from the new coronavirus strain in autoimmune/autoinflammatory and liver diseases
Abstract
dc:descriptionAs soon as the World Health Organization (WHO) declared the COVID-19 pandemic, concerns had been raised regarding the possibility of increased disease severity and adverse outcomes in patients with SAARD given the immune dysfunction in the context of autoimmunity and immunosuppressive treatment. Clinically significant questions regarding the clinical picture of COVID-19, disease severity, risk factors for adverse outcomes as well as their course before and after the introduction of vaccines and antivirals had to be answered. Additionally, concerns had been raised regarding the effect of immunosuppressive therapy on SARS-CoV-2 vaccine-induced immunogenicity, based on the precautions taken with the pneumococcal and influenza immunizations. To address these questions, we prospectively followed up patients with systemic autoimmune rheumatic diseases under immunosuppressive treatment during all major waves of the pandemic at a tertiary university hospital and other affiliated institutions. Among patients with systemic autoimmune rheumatic diseases infected for the first time by SARS-CoV-2, during the first wave of the pandemic, it was shown that the vast majority (86.8%) experienced asymptomatic, mild or moderate COVID-19; while fewer (12.8%) developed severe or critical disease necessitating hospitalization. The predominant clinical manifestations were fatigue (58.4%), low grade fever (45.4%) and upper respiratory tract symptoms (68.8%). Mortality was 1.3% comparable to that observed in the general population. Older age, lung disease in the context of the underlying rheumatic disease as well as were found to be independent predictive factors for hospitalization. As a next step, we conducted a prospective, nationwide, multicenter study, including 605 SAARD patients and 116 healthy individuals, where we prospectively evaluated serum anti-SARS-CoV-2 S1-protein IgG antibody titers, side-effects, and disease activity, one month after complete vaccination, in terms of distinct treatment modification strategies (none, partial and extended modifications). Patients with extended treatment modifications responded to vaccines similarly to controls and SAARD patients without immunosuppressive therapy. In contrast, patients with partial or without therapeutic modifications responded in 87.50% and 84.50%, respectively. Furthermore, SAARD patients with extended treatment modifications developed higher anti-SARS-CoV-2 antibody levels compared to those without or with partial modifications. MMF, RTX and MTX negatively affected anti-SARS-CoV-2 humoral responses. In 10.5% of vaccinated patients, mild clinical deterioration was noted; however, no differences in the incidence of deterioration were observed among the distinct treatment modification SAARD subgroups. Side-effects were generally comparable between SAARD patients and controls. Given that, we showed that mRNA SARS-CoV-2 vaccines are effective and safe, both in terms of side-effects and disease flares in SAARD patients. Treatment with MMF, RTX and/or MTX compromises anti-SARS-CoV-2 antibody responses, which are restored upon extended treatment modifications without affecting disease activity. Regarding the effect of vaccination on COVID-19 characteristics and outcomes, 134 vaccine-naïve, 89 2-dose vaccinated and 105 3-dose vaccinated patients with systemic rheumatic diseases who were infected with SARS-CoV- 2 were compared. The hospitalization rate was higher in the unvaccinated (26.9%) than in the 2-dose (14.6%, p = 0.03) or 3-dose (4.8%, p < 0.001) vaccinated patients. Severe/critical COVID-19 cases requiring oxygen supplementation were the least among 3-dose vaccinated (3.8%) compared to both 2-dose vaccinated (13.5%, p = 0.018) and unvaccinated (18.7%, p < 0.001) patients. ICU admission and death rates were similar among unvaccinated (3.7% and 2.2%, respectively) and 2-dose vaccinated patients (4.5%; and 2.2%, respectively), while no 3-dose vaccinated patients died or required ICU admission. Logistic regression analysis revealed a significant inverse association between 3-dose vaccination and severe/critical COVID-19 (OR = 0.078, 95% CI: 0.022–0.273, p < 0.001). Furthermore, in order to describe data on the safety and efficacy of MP and NM/R in patients with systemic autoimmune rheumatic diseases with COVID-19, 74 patients were identified who had been infected with SARS-CoV-2 and received MP (35.1%) or NM/R (64.9%). Most patients were vaccinated against SARS-CoV-2 (83.8%). During follow-up, all but 2 patients (97.3%) recovered at home without COVID-19–related complications while drug common adverse events were reported only by 4 patients receiving NM/R (metallic taste, gastrointestinal upset, hypertension), not leading to drug discontinuation. To evaluate the prevalence of autoantibodies (AAbs) in mechanically ventilated COVID-19 patients and their potential impact on clinical outcomes, we collected serum samples from 217 ICU-admitted COVID-19 patients within 48 hours of admission and tested for the presence of AAbs compare to 117 age- and sex-matched healthy pre-pandemics controls. AAbs were significantly more common in COVID-19 patients than in controls (80.2% vs. 62.4%, p < 0.001). COVID-19 patients more frequently were found positive for ANAs (48.4% vs. 21.4%, p < 0.001), anti-dsDNA (5.1% vs. 0%, p = 0.01), anti-CCP (8.3% vs. 1.7%, p = 0.014), and anti-CL IgM (21.7% vs. 9.4%, p = 0.005). Multiple autoantigen reactivity (≥3 autoantibodies) was observed in 82.8% of seropositive patients. However, no differences in clinical characteristics or ICU mortality were noted between AAb-positive and AAb-negative groups. Mortality was associated with older age, higher ferritin, D-dimers, APACHE II scores, lower oxygen saturation, and comorbidities; but not with AAbs. As such, severe COVID-19 seem to be associated with a higher prevalence of AAbs, but their presence does not influence clinical outcomes. Last but not least, to better characterize antibody responses to the novel COVID-19 vaccines in patients with liver diseases (PWLD), we prospectively assessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD (n = 87) and controls (n = 40). Seroconversion rates were 97.4% in cirrhotic PWLD, 87.8% in non-cirrhotic PWLD and 100% (40/40) in controls. Adequate neutralizing activity was detected in 92.1%, 87.8% and 100% of cirrhotics, non-cirrhotics and controls, respectively. On multivariable analysis, immunosuppressive treatment was negatively correlated with anti-SARS-CoV-2 antibody titers and neutralizing activity, while age was negatively correlated only with neutralizing activity. A total of 52 responder PWLD were reassessed approximately 3 months post-vaccination and no differences were detected in humoral responses between cirrhotic and non-cirrhotic PWLD. No significant side effects were noted post vaccination, while no symptomatic breakthrough infections were reported during a 6-month follow up. Overall, our study showed that mRNA-based SARS-CoV-2 vaccines are safe and efficacious in PWLD. However, PWLD under immunosuppressive treatment and those of advanced age should probably be more closely monitored after vaccination. Collectively, the majority of autoimmune patients display a mild COVID-19 course with specific underlying disease features and COVID-19 related manifestations increasing the risk for severe COVID-19 and hospitalization. mRNA SARS-CoV-2 vaccines are effective and safe, both in terms of side-effects and disease flares in SAARD patients; similar to vaccination among PWLD with or without cirrhosis. Treatment with MMF, RTX and/or MTX compromises anti-SARS-CoV-2 antibody responses, which are restored upon treatment modifications without affecting disease activity. Following vaccination, COVID-19 symptomatology lessens, and 3-dose vaccinated patients seem to be more protected from severe breakthrough SARS-CoV-2 infections, compared to unvaccinated or 2-dose vaccinated ones. Last, these data show a favorable outcome and acceptable safety profile of the 2 oral antiviral therapies MP and NM/R among a high-risk autoimmune rheumatic population.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Bakasis, Athanasios-Dimitrios
- Μπακάσης, Αθανάσιος-Δημήτριος
Subjects
dc:subject × 21- Ανοσολογία
- Ρευματολογία
- Ηπατολογία
- Μικροβιολογία
- COVID-19
- Κορονοϊός
- Εμβόλια
- Immunology
- Rheumatology
- Hepatology
- Microbiology
- Coronavirus
- Vaccination
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Κλινική ιατρική, γενικά
- Βασική Ιατρική
- Clinical Medicine
- Medical and Health Sciences
- Clinical medicine, general
- Basic Medicine
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58586